| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2022 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 05/12/2022 | 123.05% | Piper Sandler | $12 → $6 | Maintains | Overweight |
| 05/12/2022 | 160.22% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 03/09/2022 | 346.1% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 12/03/2021 | 346.1% | SVB Leerink | $17 → $12 | Maintains | Outperform |
| 11/16/2021 | 531.97% | SVB Leerink | → $17 | Initiates Coverage On | → Outperform |
| 11/16/2021 | 457.62% | UBS | → $15 | Initiates Coverage On | → Buy |
| 11/16/2021 | 420.45% | JP Morgan | → $14 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 531.97% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
Minerva Surgical Questions & Answers
The latest price target for Minerva Surgical (NASDAQ: UTRS) was reported by JP Morgan on August 10, 2022. The analyst firm set a price target for $0.00 expecting UTRS to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Minerva Surgical (NASDAQ: UTRS) was provided by JP Morgan, and Minerva Surgical downgraded their underweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Minerva Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Minerva Surgical was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
While ratings are subjective and will change, the latest Minerva Surgical (UTRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Minerva Surgical (UTRS) is trading at is $2.69, which is out of the analyst's predicted range.